MX2021015121A - Secuencias lider. - Google Patents

Secuencias lider.

Info

Publication number
MX2021015121A
MX2021015121A MX2021015121A MX2021015121A MX2021015121A MX 2021015121 A MX2021015121 A MX 2021015121A MX 2021015121 A MX2021015121 A MX 2021015121A MX 2021015121 A MX2021015121 A MX 2021015121A MX 2021015121 A MX2021015121 A MX 2021015121A
Authority
MX
Mexico
Prior art keywords
pvc
payload
effector
leader sequence
needle complex
Prior art date
Application number
MX2021015121A
Other languages
English (en)
Spanish (es)
Inventor
Nicholas R Waterfield
Joseph Healey
Alexia Hapeshi
Original Assignee
Univ Warwick
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Warwick filed Critical Univ Warwick
Publication of MX2021015121A publication Critical patent/MX2021015121A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/89Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microinjection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70Vectors or expression systems specially adapted for E. coli
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nanotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
MX2021015121A 2019-06-07 2020-06-05 Secuencias lider. MX2021015121A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1908155.3A GB201908155D0 (en) 2019-06-07 2019-06-07 Leader sequence
PCT/GB2020/051380 WO2020245611A1 (en) 2019-06-07 2020-06-05 Leader sequence

Publications (1)

Publication Number Publication Date
MX2021015121A true MX2021015121A (es) 2022-03-17

Family

ID=67386182

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021015121A MX2021015121A (es) 2019-06-07 2020-06-05 Secuencias lider.

Country Status (12)

Country Link
US (1) US20230076614A1 (https=)
EP (1) EP3980545A1 (https=)
JP (2) JP7748288B2 (https=)
KR (1) KR20220133757A (https=)
CN (1) CN114008205A (https=)
AU (1) AU2020288380A1 (https=)
BR (1) BR112021024592A2 (https=)
CA (1) CA3142462A1 (https=)
GB (1) GB201908155D0 (https=)
MX (1) MX2021015121A (https=)
SG (1) SG11202113297RA (https=)
WO (1) WO2020245611A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4479082A2 (en) * 2022-02-15 2024-12-25 The Broad Institute, Inc. Cell-type specific targeting contractile injection system
EP4547848A1 (en) 2022-06-30 2025-05-07 Københavns Universitet Contractile injection system and use thereof
CN119735656A (zh) * 2023-09-22 2025-04-01 北京朝赛蕴生物科技有限公司 一种蛋白复合物的制备纯化及应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
JP6283040B2 (ja) * 2013-03-07 2018-02-21 ザ ジェネラル ホスピタル コーポレイション 細菌によるポリペプチド送達のための組成物および方法
EP3362466B1 (en) * 2015-10-14 2023-06-14 BASF Agricultural Solutions Seed US LLC Axmi554 delta-endotoxin gene and methods for its use

Also Published As

Publication number Publication date
US20230076614A1 (en) 2023-03-09
JP2025114573A (ja) 2025-08-05
WO2020245611A1 (en) 2020-12-10
BR112021024592A2 (pt) 2022-01-18
JP2022535283A (ja) 2022-08-05
GB201908155D0 (en) 2019-07-24
EP3980545A1 (en) 2022-04-13
AU2020288380A1 (en) 2022-01-06
SG11202113297RA (en) 2021-12-30
JP7748288B2 (ja) 2025-10-02
KR20220133757A (ko) 2022-10-05
CN114008205A (zh) 2022-02-01
CA3142462A1 (en) 2020-12-10

Similar Documents

Publication Publication Date Title
MX2021015121A (es) Secuencias lider.
BR112021026376A2 (pt) Proteínas de fusão flt3l-fc e métodos de uso
CO2022010422A2 (es) Anticuerpo anti antígeno-4 asociado al linfocito t citotóxico (ctla-4) y uso del mismo
CL2021003191A1 (es) Inhibidores de tead y usos de los mismos
CO2019000395A2 (es) Genes de mini–distrofina optimizados y casetes de expresión y su uso
CO2021017650A2 (es) Vectores víricos y uso de los mismos en terapias celulares adoptivas
AR114275A1 (es) Anticuerpos anti-cd73 y métodos de uso de los mismos
MX2020004578A (es) Composiciones de casz y metodos de uso.
MX2020013579A (es) Componentes cascada y complejos cascada producidos por ingenieria.
MX2020007799A (es) Inhibidores de cinasa no derrepresible de control de aminoacido general 2 (gcn2) y sus usos.
MX2021001098A (es) Anticuerpos de un solo dominio dirigidos contra antigenos intracelulares.
CR20220330A (es) Anticuerpos anti-ly6g6d y métodos de uso.
NI201800113A (es) Anticuerpos anti-basigin humanizados y uso de los mismos.
CL2020000606A1 (es) Sistema de expresión de paramyxoviridae.
CL2022000193A1 (es) Composición de vacuna y sus usos para el control o la prevención de una infestación por piojos de mar (divisional de la solicitud no. 201900422)
PT4219688T (pt) Células t invariantes associadas à mucosa (mait) que expressam recetores de antigénio quiméricos
UY37406A (es) Nuevo sitio de inserción orf70 de ehv
PY1965502A (es) Activadores de la vía inducible del gen "rig-i" del ácido retinoico y métodos de uso de los mismos
CL2023001666A1 (es) Composiciones de los agentes de unión a antígenos de la guanilil ciclasa c (gcc) y sus métodos de uso
MX2018003445A (es) Expresion de proteinas que contienen fc.
BR112018001967A2 (pt) material de gravação sensível ao calor.
MX2019003160A (es) Nuevos promotores.
AR108642A1 (es) Benzimidazoles sustituidos como inhibidores de irak4 y su uso para la preparación de medicamentos
CL2024000116A1 (es) Identificación de receptores y antígenos de células t específicos de tumores comunes
BR112021024655A2 (pt) Reagente de diagnóstico